AstraZeneca PLC (LON:AZN) Receives GBX 7,542.80 Consensus Price Target from Brokerages

AstraZeneca PLC (LON:AZN) has been assigned an average rating of “Moderate Buy” from the seven analysts that are presently covering the stock, Marketbeat reports. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is GBX 7,542.80 ($94.85).

Several research firms have recently commented on AZN. JPMorgan Chase & Co. reissued an “overweight” rating on shares of AstraZeneca in a report on Wednesday, February 19th. Berenberg Bank reaffirmed a “buy” rating and set a GBX 140 ($1.76) price objective on shares of AstraZeneca in a report on Monday, January 27th. Finally, Shore Capital reaffirmed a “buy” rating on shares of AstraZeneca in a report on Thursday, November 7th.

AstraZeneca Stock Down 0.4 %

AZN opened at £119.70 ($150.53) on Monday. The company has a debt-to-equity ratio of 73.83, a current ratio of 0.93 and a quick ratio of 0.59. The business has a 50 day simple moving average of £111.51 and a 200-day simple moving average of £114.49. The stock has a market capitalization of £230.30 billion, a P/E ratio of 32.81, a P/E/G ratio of 0.86 and a beta of 0.17. AstraZeneca has a 12 month low of GBX 9,670 ($121.60) and a 12 month high of £133.88 ($168.36).

About AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.